Ajanta Pharma Share Price Surges 5% on Semaglutide Marketing Pact with Biocon

Ajanta Pharma shares jumped 5% to close at Rs 2,810 per share on December 24, marking a five-month high. The sudden uptick comes after the company signed a strategic in-licensing agreement with Biocon to market the weight-loss drug Semaglutide.

This move has caught the attention of investors tracking Ajanta Pharma share price and broader stock market today trends, highlighting the growing interest in pharma companies leveraging global partnerships.

Market Performance: Pharma Stocks in Focus

The announcement had an immediate impact on Ajanta Pharma’s market performance:

• Ajanta Pharma shares: Up 5% to Rs 2,810
• Nifty Pharma index: Down 2% year-to-date
• Biocon shares: Rose 0.5% on December 24

Despite the volatility in the pharma sector this year, Ajanta Pharma’s move has provided a positive trigger for the stock, especially in the context of its five-month high.

The Biocon Pact: What It Means?

Ajanta Pharma’s agreement with Biocon revolves around the marketing of Semaglutide, a GLP-1 receptor agonist used to improve glycaemic control in adults. Key details include:

• Exclusive marketing rights in 23 countries
• Semi-exclusive marketing rights in three countries across Africa, West Asia, and Central Asia
• Supply by Biocon, ensuring a smooth rollout once regulatory approvals are in place

Semaglutide’s patent expiry in most of these markets is March 2026, which positions Ajanta Pharma to begin commercialization in late 2026 or early 2027.

This deal highlights Ajanta Pharma’s focus on growing its international footprint and capitalizing on the rising demand for weight-loss and metabolic disorder treatments.

Company Details: Ajanta Pharma at a Glance

Ajanta Pharma has been making strategic moves to strengthen its global portfolio. Highlights relevant to the Semaglutide deal:

• Operates across multiple international markets
• Focus on therapeutic segments like ophthalmology, dermatology, cardiology, and metabolic disorders
• 2025 performance saw a 5% dip in share price, contrasting the recent 5% surge

The recent agreement adds a growth catalyst without altering the company’s core fundamentals, emphasizing long-term strategic expansion.

Summary: Stock Market Today and Ajanta Pharma Outlook

On December 24, Ajanta Pharma’s share price rally highlighted its strategic partnership with Biocon, signaling investor optimism around global pharma collaborations.

Key takeaways for the stock market today:

• Ajanta Pharma is rebounding after a 5% drop earlier in 2025
• The Biocon deal provides exclusive and semi-exclusive marketing opportunities
• Regulatory approvals for Semaglutide are expected in late 2026 or early 2027
• Pharma sector trends remain volatile, but selective partnerships continue to drive share movements

In short, Ajanta Pharma is leveraging global agreements to create growth pathways and investor interest, making its share price movement one to watch in the coming months.

Source: Moneycontrol